- Overview of CLL Diagnosis and Evaluation
- Symptoms and diagnosis
- Risk assessment and prognostic factors
- Case Discussions
- Case 1: An otherwise healthy patient diagnosed with CLL without del(17p)
- Case 2: An elderly, frail patient diagnosed with CLL without del(17p)
- Case 3: A patient diagnosed with CLL and del(17p) and/or TP53 mutation
- Case 4: A patient with normal-risk CLL and relapse on chemoimmunotherapy
- Case 5: A patient with high-risk CLL and relapse on ibrutinib
- Case 6: A elderly patient with CLL and intolerance to ibrutinib
- Case 7: A patient with CLL and multiple relapses (chemoimmunotherapy and a targeted therapy)
- For each patient scenario, discussion will include
- 5 CLL expert recommendations from the continually updated decision support tool for each case scenario
- Review of key factors to consider in developing management recommendations
- Rationale for agent sequencing for each case scenario
- Management of treatment-related adverse events
- Near future directions: promising agents and combinations under investigation
- Review of practice-changing data on novel combination regimens
Date / Time
The goal of this activity is to improve participants’ ability to optimize patient outcomes through live workshops and resources that support a shared decision making approach between clinicians and patients and that accelerate the awareness and integration of current best practices in the treatment of chronic lymphocytic leukemia.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers and their patients with chronic lymphocytic leukemia.
- Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed chronic lymphocytic leukemia
- Choose optimal treatment for relapsed/refractory chronic lymphocytic leukemia based on the available clinical data and expert recommendations
- Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life
- Evaluate promising investigational agents and novel combination regimens in chronic lymphocytic leukemia, including efficacy, unique toxicities, and other practical management considerations
- Manage adverse events associated with treatment approaches for chronic lymphocytic leukemia to ensure treatment compliance as well as improved clinical outcomes and quality of life
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this activity is 1.0 contact hour.
Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-020-L01-P.
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.